TP53 and thalassemia: Aim of our study was to determine the frequency of MGMT promoter methylation in a cohort of WHO grade 4 diffuse glioma patients and correlate the findings with various clinical, pathological and immunohistochemical markers expression, specifically IDH1, tumor protein 53 (TP53), alpha-thalassemia/mental retardation syndrome X-linked (ATRX), and Ki-67 proliferation index.